Study of GTX-B001 for chronic inducible urticaria
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new drug, GTX-B001, in healthy people and those with a type of hives called chronic inducible urticaria (specifically cold-induced or scratch-induced hives). The goal is to see if it's safe and helps control symptoms that don't respond well to standard antihistamines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old (or 18–55 if healthy).
- You have had cold- or scratch-induced hives for at least 3 months.
- Your hives are not well controlled with a second-generation antihistamine (like cetirizine or loratadine).
- You have a positive test result for cold- or scratch-induced hives during screening.
- You have not used certain immune-modulating medications (like steroids, biologics, or other experimental drugs) within the last month (or longer for some).
- You do not have other significant health conditions or skin diseases that could interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called barzolvolimab for people with cold-induced hives or a condition where scratching causes raised lines (symptomatic dermographism) that aren't well controlled by antihistamines. The study compares the drug to a placebo to see if it reduces itching and hives.
This study aims to better understand inducible urticaria (hives triggered by cold, pressure, or friction) and chronic spontaneous urticaria. Researchers will use skin tests to measure how different triggers affect your skin in detail.
This trial tests a new medicine called BBT001 for people with chronic spontaneous urticaria (long-lasting hives without a known cause). It aims to see if the drug is safe and helps reduce itching and hives.
This trial tests a new oral medication for chronic spontaneous urticaria (chronic hives). It is a placebo-controlled study, meaning some participants will get the new drug and some will get a placebo (a pill with no active ingredient). The goal is to see if the new drug is safe and how well it works, possibly providing a new treatment option for those whose hives are not controlled by current antihistamines.
This trial tests a new oral medication called tacabrutideg (BGB-16673) for chronic spontaneous urticaria, a condition with frequent hives and itching. It aims to see how safe it is and how well it works, possibly offering a new option for people who still have symptoms despite antihistamines.
This study tests an experimental capsule (HS-10561) to see if it is safe and works for people with chronic spontaneous urticaria, which causes hives and itching without a clear trigger. If you have had hives for at least 6 months, you might be able to join.
Hear when a new Chronic Inducible Urticaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.